Charles Schwab Investment Management Inc Halozyme Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,783,177 shares of HALO stock, worth $106 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,783,177
Previous 1,773,397
0.55%
Holding current value
$106 Million
Previous $101 Million
15.97%
% of portfolio
0.02%
Previous 0.02%
Shares
30 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$791 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$428 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$248 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$205 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.29B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...